GlaxoSmithKline-owned ViiV Healthcare makes huge HIV breakthrough
There was a time when a HIV diagnosis was seen as a death sentence. Thanks to a slew of medical breakthroughs over the last 30 years, that’s no longer the case – and now, thanks to a new breakthrough, the once-deadly virus may be easier to suppress than ever! ViiV, which is owned by GlaxoSmithKline (GSK), Pfizer, and Shionogi, has developed a once-a-month jab which could replace the daily cocktail of drugs currently used to treat HIV.
GlaxoSmithKline’s share price has risen by 16% so far this year
SOURCE: Yahoo Finance
According to reports, ViiV’s new treatment is just as effective (i.e.: very effective) as the current treatment on offer – but it is far, far, more convenient. That’s great news for sufferers from an ease-of-use perspective, but it’s also a massive step treatment-wise: only having to remember to do one thing a month, rather than multiple things a day, means there’s far less chance of patients forgetting to take their medication, which makes the virus easier to combat.
A phase three efficacy study, called ATLAS (Antiretroviral Therapy as Long Acting Suppression) was used to assess how effective the drug was over 48 weeks. The results indicate that it is equally effective to current treatments.
John Pottage, ViiV’s chief scientific and medical officer, told reporters: “If approved, this regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12."
That’s a huge impact on the life of HIV positive people, and it’s a big step forward for healthcare and the fight against AIDS. It might also, if the required approvals are imminent, be a welcome discovery for investors.
Dominion holds GlaxoSmithKline in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.